Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
HR

NASDAQ · HROW

Harrow Health, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$28.95

Up+$0.51 (+1.79%)

Updated Oct 27, 2026, 3:41 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.89B
P/E ratio
-183.74
Dividend yield
0.00%
52-week range
$26.96 – $47.50
Volume
499.15K
Avg. volume
738.98K

Price performance · HROW

HROW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

HROW closed at $28.95 after 21 trading sessions, down 8.39% for the selected period.

Last close
$28.95
Period change
-8.39%
Period low
$27.24
Period high
$31.60
Daily close
View OHLC price history
HROW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$28.61$29.48$28.30$28.95499.15K
Oct 23, 2026$27.76$28.555$27.14$28.44854.71K
Oct 22, 2026$27.82$28.45$27.702$28.15440.12K
Oct 21, 2026$28.26$28.66$27.98$28.24524.42K
Oct 20, 2026$27.70$29.25$27.70$28.07526.97K
Oct 19, 2026$27.40$28.53$27.40$27.68576.13K
Oct 16, 2026$28.59$28.665$27.13$27.28560.47K
Oct 15, 2026$27.14$28.92$27.03$28.75583.47K
Oct 14, 2026$28.00$28.31$26.96$27.24660.46K
Oct 13, 2026$28.96$29.425$28.03$28.24807.08K
Oct 12, 2026$29.38$29.73$28.86$29.11577.03K
Oct 9, 2026$30.73$30.90$27.00$29.361.35M
Oct 8, 2026$30.35$31.11$30.00$30.52566.01K
Oct 7, 2026$30.09$31.11$29.90$30.62708.53K
Oct 6, 2026$30.86$30.90$29.845$30.35422K
Oct 5, 2026$31.43$31.43$30.43$30.58587.35K
Oct 2, 2026$30.83$30.97$30.15$30.48566.38K
Oct 1, 2026$30.55$31.10$30.275$30.61597.21K
Sep 30, 2026$31.62$31.86$30.76$30.80514.37K
Sep 29, 2026$31.60$31.82$31.09$31.40396.82K
Sep 28, 2026$32.61$32.88$30.19$31.60852.45K

Latest HROW news

The latest Smart Investors Daily articles mentioning HROW.

Stock researchCompany · Overview

HROW research

Overview

Company profile and research snapshot.

Company profile

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.00
Implied upside
—
Analysts
—
HROW recent ratings
DateFirmRatingTarget
Oct 7, 2026BTIGBuy—
Sep 9, 2026Leerink PartnersOutperform—
Aug 11, 2026BTIGBuy—
Jul 21, 2026BTIGBuy—
May 13, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 18, 2026

Is Harrow (HROW) Below Fair Value Based On Its Sales?

Harrow has given shareholders a bumpy ride lately, which puts fresh attention on a simple question for you as an investor. Does the current share price make sense when you line it up against the business and its sales base? Over the past 5 years, Harrow has returned 180.1%, which puts a lot of past optimism about its revenue potential under the microscope. The company’s value now leans heavily on how effectively it can turn its existing product portfolio and commercial footprint into...

Yahoo · Oct 8, 2026

Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?

Conference spotlight puts Harrow’s ophthalmic pipeline in focus Harrow (HROW) is set to present 15 scientific abstracts across its ophthalmic portfolio at the American Academy of Optometry and American Academy of Ophthalmology meetings starting September 30, 2026. Those sessions span dry eye disease, vernal keratoconjunctivitis, ocular inflammation, chronic blepharitis, and post operative inflammation and pain. They include Phase 3 data, long term safety results, comparative studies, and real...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By